Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SAB Biotherapeutics, Inc.SABS · Entity 5816 | Director | December 16, 2025 | December 18, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SAB Biotherapeutics, Inc.
Report date December 16, 2025 · Filed December 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.99 · Expires 2035-12-16 | Direct | 150,000 |
Reported balance
After 2025-12-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-16 · Grant · Acquired 150,000 · Balance 150,000 F1: Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027. F2: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027.
F2: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 16, 2025 Filed Dec 18, 2025 21:43 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001193125-25-324970 · ownership.xml · derivative · entry 1 Giberson Scott · CIK 0001937585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2035-12-16 F1 · security: Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027. F2 · security: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended. F1 · derivative.exercise_date: Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:30 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0000950170-24-084288 · ownership.xml · derivative · entry 1 Giberson Scott · CIK 0001937585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-07-15 F1 · security: Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026. F2 · security: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended. F1 · derivative.exercise_date: Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026. Read SEC document |
| September 13, 2022 Filed Sep 15, 2022 21:00 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantEmployee Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001209191-22-050094 · doc4.xml · derivative · entry 1 Giberson Scott · CIK 0001937585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-09-13 F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The shares underlying the option vest over a three-year period, vesting 1/36 monthly beginning with the month following the Reporting Person's commencement of service as a director (July 6, 2022). This represents the initial grant to the Reporting Person as a member of the Board of Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.